333 related articles for article (PubMed ID: 27483001)
21. OPTIMAL and ENSURE trials-based combined cost-effectiveness analysis of erlotinib versus chemotherapy for the first-line treatment of Asian patients with non-squamous non-small-cell lung cancer.
Wen F; Zheng H; Zhang P; Hutton D; Li Q
BMJ Open; 2018 Apr; 8(4):e020128. PubMed ID: 29654023
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China.
Gu X; Zhang Q; Chu YB; Zhao YY; Zhang YJ; Kuo D; Su B; Wu B
Lung Cancer; 2019 Jan; 127():84-89. PubMed ID: 30642557
[TBL] [Abstract][Full Text] [Related]
23. From Diagnostic-Therapeutic Pathways to Real-World Data: A Multicenter Prospective Study on Upfront Treatment for
Pasello G; Vicario G; Zustovich F; Oniga F; Gori S; Rosetti F; Bonetti A; Favaretto A; Toso S; Redelotti R; Santo A; Bernardi D; Giovanis P; Oliani C; Calvetti L; Gatti C; Palazzolo G; Baretta Z; Bortolami A; Bonanno L; Basso M; Menis J; Corte DD; Frega S; Guarneri V; Conte P;
Oncologist; 2019 Jun; 24(6):e318-e326. PubMed ID: 30846513
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung.
de Lima Lopes G; Segel JE; Tan DS; Do YK; Mok T; Finkelstein EA
Cancer; 2012 Feb; 118(4):1032-9. PubMed ID: 21792863
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3.
Borget I; Cadranel J; Pignon JP; Quoix E; Coudert B; Westeel V; Dansin E; Madelaine J; Madroszyk A; Friard S; Daniel C; Morin F; Chouaid C;
Eur Respir J; 2012 Jan; 39(1):172-9. PubMed ID: 21659409
[TBL] [Abstract][Full Text] [Related]
26. Incremental cost-effectiveness analysis of tyrosine kinase inhibitors in advanced non-small cell lung cancer with mutations of the epidermal growth factor receptor in Colombia.
Lasalvia P; Hernández F; Gil-Rojas Y; Rosselli D
Expert Rev Pharmacoecon Outcomes Res; 2021 Aug; 21(4):821-827. PubMed ID: 32498573
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of precision medicine in the fourth-line treatment of metastatic lung adenocarcinoma: An early decision analytic model of multiplex targeted sequencing.
Doble B; John T; Thomas D; Fellowes A; Fox S; Lorgelly P
Lung Cancer; 2017 May; 107():22-35. PubMed ID: 27316470
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of ALK testing and first-line crizotinib therapy for non-small-cell lung cancer in China.
Lu S; Yu Y; Fu S; Ren H
PLoS One; 2018; 13(10):e0205827. PubMed ID: 30352060
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations.
Holleman MS; Al MJ; Zaim R; Groen HJM; Uyl-de Groot CA
Eur J Health Econ; 2020 Feb; 21(1):153-164. PubMed ID: 31541309
[TBL] [Abstract][Full Text] [Related]
30. Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer.
Bradbury PA; Tu D; Seymour L; Isogai PK; Zhu L; Ng R; Mittmann N; Tsao MS; Evans WK; Shepherd FA; Leighl NB;
J Natl Cancer Inst; 2010 Mar; 102(5):298-306. PubMed ID: 20160168
[TBL] [Abstract][Full Text] [Related]
31. Cost-utility of afatinib and gefitinib as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer.
Wang H; Zeng C; Li X; Wang Y; Li X; Ge W
Future Oncol; 2019 Jan; 15(2):181-191. PubMed ID: 30320506
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness of erlotinib versus docetaxel for second-line treatment of advanced non-small-cell lung cancer in the United Kingdom.
Lewis G; Peake M; Aultman R; Gyldmark M; Morlotti L; Creeden J; de la Orden M
J Int Med Res; 2010; 38(1):9-21. PubMed ID: 20233509
[TBL] [Abstract][Full Text] [Related]
33. A Cost-Effectiveness Analysis of Using the JBR.10-Based 15-Gene Expression Signature to Guide Adjuvant Chemotherapy in Early Stage Non-Small-Cell Lung Cancer.
Wong KM; Ding K; Li S; Bradbury P; Tsao MS; Der SD; Shepherd FA; Chung C; Ng R; Seymour L; Leighl NB
Clin Lung Cancer; 2017 Jan; 18(1):e41-e47. PubMed ID: 27502323
[TBL] [Abstract][Full Text] [Related]
34. Healthcare costs in patients with advanced non-small cell lung cancer and disease progression during targeted therapy: a real-world observational study.
Skinner KE; Fernandes AW; Walker MS; Pavilack M; VanderWalde A
J Med Econ; 2018 Feb; 21(2):192-200. PubMed ID: 29041833
[TBL] [Abstract][Full Text] [Related]
35. Erlotinib or best supportive care for third-line treatment of advanced non-small-cell lung cancer: a real-world cost-effectiveness analysis.
Cromwell I; van der Hoek K; Malfair Taylor SC; Melosky B; Peacock S
Lung Cancer; 2012 Jun; 76(3):472-7. PubMed ID: 22226627
[TBL] [Abstract][Full Text] [Related]
36. Erlotinib treatment after platinum-based therapy in elderly patients with non-small-cell lung cancer in routine clinical practice - results from the ElderTac study.
Brueckl WM; Achenbach HJ; Ficker JH; Schuette W
BMC Cancer; 2018 Mar; 18(1):333. PubMed ID: 29587656
[TBL] [Abstract][Full Text] [Related]
37. Cost-Effectiveness of Osimertinib in Treating Newly Diagnosed, Advanced EGFR-Mutation-Positive Non-Small Cell Lung Cancer.
Wu B; Gu X; Zhang Q; Xie F
Oncologist; 2019 Mar; 24(3):349-357. PubMed ID: 30257889
[TBL] [Abstract][Full Text] [Related]
38. Acquired Resistance to Erlotinib in EGFR Mutation-Positive Lung Adenocarcinoma among Hispanics (CLICaP).
Cardona AF; Arrieta O; Zapata MI; Rojas L; Wills B; Reguart N; Karachaliou N; Carranza H; Vargas C; Otero J; Archila P; Martín C; Corrales L; Cuello M; Ortiz C; Pino LE; Rosell R; Zatarain-Barrón ZL;
Target Oncol; 2017 Aug; 12(4):513-523. PubMed ID: 28620690
[TBL] [Abstract][Full Text] [Related]
39. Osimertinib in first-line treatment of advanced EGFR-mutated non-small-cell lung cancer: a cost-effectiveness analysis.
Aguilar-Serra J; Gimeno-Ballester V; Pastor-Clerigues A; Milara J; Marti-Bonmati E; Trigo-Vicente C; Alós-Almiñana M; Cortijo J
J Comp Eff Res; 2019 Aug; 8(11):853-863. PubMed ID: 31478399
[No Abstract] [Full Text] [Related]
40. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW
Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]